Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Burning Rock BiotechBNR -6.16%59 Pretax Margin % is -15.97% as of Mar. 2026. GuruFocus rates BNR with a GF Score™ of 59/100 and a GF Value™ of $7.47 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Burning Rock Biotech ranks worse than 58.42% on this metric.
The historical rank and industry rank for Burning Rock Biotech's Pretax Margin % or its related term are showing as below:
BNR'
s Pretax Margin % Range Over the Past 10 Years
Min: -172.09 Med: -94.73 Max: -9.97
Current: -11.27
BNR's Pretax Margin % is ranked worse than 58.42% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.565
vs BNR: -11.27
Burning Rock Biotech (NAS:BNR) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Burning Rock Biotech Pretax Margin % Related Terms
Burning Rock Biotech Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Burning Rock Biotech's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BNR vs XGN, IDXG, PRPO: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, Burning Rock Biotech's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Burning Rock Biotech Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Burning Rock Biotech's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Burning Rock Biotech (BNR) has a Pretax Margin % of -15.97% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Burning Rock Biotech and its competitors. According to the industry distribution chart, Burning Rock Biotech ranks #118 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 58.4%.
Is Burning Rock Biotech's Pretax Margin % too high?
Burning Rock Biotech's current Pretax Margin % is -15.97%. Based on the distribution chart, Burning Rock Biotech ranks #118 out of 202 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Burning Rock Biotech has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's Pretax Margin % compare to XGN and IDXG?
According to the Medical Diagnostics & Research industry distribution chart, Burning Rock Biotech ranks #118 out of 202 companies for Pretax Margin %. This places Burning Rock Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Burning Rock Biotech and its competitors. Burning Rock Biotech's current Pretax Margin % is -15.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (BNR) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.47, compared to a current price of $9.45 — trading 26.5% above its estimated fair value. The current Pretax Margin % is -15.97%. Burning Rock Biotech's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Burning Rock Biotech (BNR), the current Pretax Margin % is -15.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Burning Rock Biotech (BNR) Overvalued in 2026?
Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued.
The current stock price of $9.45 is trading 26.5% above its estimated GF Value™ of $7.47.
GuruFocus considers Burning Rock Biotech to be Modestly Overvalued.
Key valuation signals for BNR:
Pretax Margin %: -15.97%
GF Value™: $7.47 vs. price of $9.45 (26.5% above fair value)
No single metric tells the full story. See the BNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
59GF Score
Get the complete analysis for BNR
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNR has been successfully added to your 
